Similar articles for PMID: 21795361

Year	Number of Results
1992	1
1994	1
1998	1
2001	1
2002	2
2003	3
2004	2
2005	6
2006	7
2007	3
2008	5
2009	4
2010	10
2011	7
2012	9
2013	10
2014	14
2015	16
2016	19
2017	16
2018	14
2019	13
2020	7
2021	6
2022	5
2023	1
2024	0

1

Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate.

Khan S, Krenning EP, van Essen M, Kam BL, Teunissen JJ, Kwekkeboom DJ. Khan S, et al. J Nucl Med. 2011 Sep;52(9):1361-8. doi: 10.2967/jnumed.111.087932. Epub 2011 Jul 27. J Nucl Med. 2011. PMID: 21795361 Free article.

2

Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate.

Teunissen JJ, Kwekkeboom DJ, Krenning EP. Teunissen JJ, et al. J Clin Oncol. 2004 Jul 1;22(13):2724-9. doi: 10.1200/JCO.2004.10.016. J Clin Oncol. 2004. PMID: 15226340 Clinical Trial.

3

Long-Term Efficacy, Survival, and Safety of [¹⁷⁷Lu-DOTA⁰,Tyr³]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors.

Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, van Eijck CHJ, Franssen GJH, Krenning EP, Kwekkeboom DJ. Brabander T, et al. Clin Cancer Res. 2017 Aug 15;23(16):4617-4624. doi: 10.1158/1078-0432.CCR-16-2743. Epub 2017 Apr 20. Clin Cancer Res. 2017. PMID: 28428192

4

Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30.

Marinova M, Mücke M, Mahlberg L, Essler M, Cuhls H, Radbruch L, Conrad R, Ahmadzadehfar H. Marinova M, et al. Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):38-46. doi: 10.1007/s00259-017-3816-z. Epub 2017 Sep 1. Eur J Nucl Med Mol Imaging. 2018. PMID: 28864881

5

Comparison of response evaluation in patients with gastroenteropancreatic and thoracic neuroendocrine tumors after treatment with [177Lu-DOTA0,Tyr3]octreotate.

van Vliet EI, Krenning EP, Teunissen JJ, Bergsma H, Kam BL, Kwekkeboom DJ. van Vliet EI, et al. J Nucl Med. 2013 Oct;54(10):1689-96. doi: 10.2967/jnumed.112.117408. J Nucl Med. 2013. PMID: 24084705 Free article.

6

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate.

Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, de Jong M, Srinivasan A, Erion JL, Krenning EP. Kwekkeboom DJ, et al. Eur J Nucl Med Mol Imaging. 2003 Mar;30(3):417-22. doi: 10.1007/s00259-002-1050-8. Epub 2003 Jan 9. Eur J Nucl Med Mol Imaging. 2003. PMID: 12634971 Free PMC article. Clinical Trial.

7

Tumor response assessment to treatment with [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors: differential response of bone versus soft-tissue lesions.

van Vliet EI, Hermans JJ, de Ridder MA, Teunissen JJ, Kam BL, de Krijger RR, Krenning EP, Kwekkeboom DJ. van Vliet EI, et al. J Nucl Med. 2012 Sep;53(9):1359-66. doi: 10.2967/jnumed.112.102871. Epub 2012 Jul 10. J Nucl Med. 2012. PMID: 22782312 Free article.

8

Salvage peptide receptor radionuclide therapy with [¹⁷⁷Lu-DOTA,Tyr³]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours.

van der Zwan WA, Brabander T, Kam BLR, Teunissen JJM, Feelders RA, Hofland J, Krenning EP, de Herder WW. van der Zwan WA, et al. Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):704-717. doi: 10.1007/s00259-018-4158-1. Epub 2018 Sep 28. Eur J Nucl Med Mol Imaging. 2019. PMID: 30267116 Free PMC article.

9

Comparison of 111In-[DTPA0]Octreotide Versus Non Carrier Added 177Lu- [DOTA0,Tyr3]-Octreotate Efficacy in Patients With GEP-NET Treated Intra-arterially for Liver Metastases.

Limouris GS, Poulantzas V, Trompoukis N, Karfis I, Chondrogiannis S, Triantafyllou N, Gennimata V, Moulopoulou LE, Patsouris E, Nikou G, Michalaki V, Fragulidis G, Paphiti M, McCready RV, Colletti PM, Cook GJ, Rubello D. Limouris GS, et al. Clin Nucl Med. 2016 Mar;41(3):194-200. doi: 10.1097/RLU.0000000000001096. Clin Nucl Med. 2016. PMID: 26673241

10

Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.

De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, Bakker WH, Smith C, Pauwels S, Krenning EP. De Jong M, et al. Semin Nucl Med. 2002 Apr;32(2):133-40. doi: 10.1053/snuc.2002.31027. Semin Nucl Med. 2002. PMID: 11965608 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

164 results

Results by year